Linking QbD Activities to KRIs, QTLs and Monitoring Strategies
Linking QbD Activities to KRIs, QTLs and Monitoring Strategies Linking QbD Activities to KRIs, QTLs and Monitoring Strategies In the regulatory landscape of pharma clinical trials, the application of Quality by Design (QbD) has emerged as a pivotal regulatory strategy. This comprehensive guide focuses on linking QbD activities to Key Risk Indicators (KRIs), Quality Tolerance…
Read More “Linking QbD Activities to KRIs, QTLs and Monitoring Strategies” »